BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Actemra / RoActemra (tocilizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Actemra / RoActemra (tocilizumab)\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05874505-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0587450
 5)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: "Compariso
 n of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Sever
 e Uveitis of Behçet's Disease"\nEstimated primary completion: November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05874505
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254637-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0725463
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Tocilizuma
 b in Chronic Inflammatory CPPD Disease\nEstimated primary completion: Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 254637
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04691817-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT04691
 817)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: Tocilizu
 mab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Sma
 ll Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Bas
 ed Therapy\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04691817
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06430736-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0643073
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: PRONTO Tri
 al (PRophylactic Versus ON-demand Use of TOcilizumab)\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06430736
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05640271-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0564027
 1)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Tocilizuma
 b for Acute Chest Syndrome\nEstimated primary completion: December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05640271
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04363853-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0436385
 3)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2\, COVID-19.\nStudy:
  Tocilizumab Treatment in Patients With COVID-19\nEstimated primary comple
 tion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04363853
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077723-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT04077
 723)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 to Evaluate the Safety\, Pharmacokinetics and Preliminary Anti-Tumor Activ
 ity of Englumafusp Alfa in Combination With Obinutuzumab and in Combinatio
 n With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Partic
 ipants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma\nEstimated p
 rimary completion: 28 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04077723
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07006532-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Actemra / RoActemra (tocilizumab): Phase na readout est. (NCT070065
 32)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase na.\nStudy: Treatment
  of Chronic Active Antibody Mediated Rejection With Tocilizumab\nEstimated
  primary completion: 1 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07006532
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04616248-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270109
DTEND;VALUE=DATE:20270110
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0461624
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: In Situ Im
 munomodulation With CDX-301\, Radiation Therapy\, CDX-1140 and Poly-ICLC i
 n Patients w/ Unresectable and Metastatic Solid Tumors\nEstimated primary 
 completion: 9 January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04616248
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05391750-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0539175
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: Venetoclax
  and Tocilizumab for the Treatment of Patients With Relapsed or Refractory
  t(11\;14) Multiple Myeloma\nEstimated primary completion: 12 February 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05391750
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334379-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0733437
 9)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Interleuki
 n-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospita
 lized With Acute Respiratory Symptoms - a Feasibility Study\nEstimated pri
 mary completion: 20 February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07334379
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535244-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT05535
 244)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturatio
 n Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple My
 eloma\nEstimated primary completion: 26 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05535244
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624085-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0662408
 5)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Study Ev
 aluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin
  in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphom
 a\nEstimated primary completion: 22 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06624085
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06818266-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0681826
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: Efficacy a
 nd Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients Wi
 th Sickle Cell Disease\nEstimated primary completion: April 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06818266
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509645-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0750964
 5)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: Efficacy a
 nd Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular T
 reatment in Patients With Acute Posterior Circulation Large Vessel Occlusi
 on Stroke\nEstimated primary completion: 20 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07509645
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03448042-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0344804
 2)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Study of
  Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expr
 essing Cancers\nEstimated primary completion: 30 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03448042
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03821246-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0382124
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Neoadjuvan
 t Atezolizumab-Based Combination Therapy in Men With Localized Prostate Ca
 ncer Prior to Radical Prostatectomy\nEstimated primary completion: 30 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03821
 246
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03564340-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT03564
 340)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: Study of
  REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplima
 b in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin
 -16 Expressing (MUC16+) Cancers\nEstimated primary completion: 10 May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03564340
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108387-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0710838
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Tocilizuma
 b Discontinuation Versus Dose Reduction for Patients With Well-Controlled 
 Giant Cell Arteritis\nEstimated primary completion: 11 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07108387
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941376-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0694137
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Pragmatic\
 , Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Po
 lychondritis\nEstimated primary completion: July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06941376
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524871-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT04524
 871)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatme
 nt Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)\n
 Estimated primary completion: 30 July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04524871
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05927571-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0592757
 1)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Study Ev
 aluating the Safety\, Pharmacokinetics\, and Activity of the Combination o
 f Cevostamab and Elranatamab in Participants With Relapsed or Refractory M
 ultiple Myeloma (R/R MM)\nEstimated primary completion: 31 July 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05927571
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03708224-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0370822
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Preoperati
 ve Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and 
 Neck\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03708224
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972135-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0597213
 5)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Outpatient
  Administration of Teclistamab or Talquetamab for Multiple Myeloma\nEstima
 ted primary completion: August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05972135
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04007029-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0400702
 9)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: Modified I
 mmune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or
  Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia\nEstimated pri
 mary completion: 1 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04007029
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084936-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0608493
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: A Study to
  Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Partic
 ipants With Relapsed/Refractory Mantle Cell Lymphoma\nEstimated primary co
 mpletion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06084936
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774247-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0777424
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Atezolizum
 ab\, Bevacizumab\, and Tocilizumab in Advanced Hepatocellular Carcinoma\nE
 stimated primary completion: 1 September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07774247
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05207670-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0520767
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: A Study Ev
 aluating the Safety\, Efficacy\, and Pharmacokinetics of Mosunetuzumab Mon
 otherapy in Participants With Select B-Cell Malignancies\nEstimated primar
 y completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05207670
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609940-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 4 readout est. (NCT0760994
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 4.\nStudy: Adult Outp
 atient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of 
 Cytokine Release Syndrome (CRS)\nEstimated primary completion: 11 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0760994
 0
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05835986-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0583598
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A First-in
 -Human Study to Investigate the Safety\, Tolerability\, Pharmacokinetics a
 nd Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Eryth
 ematosus\nEstimated primary completion: 30 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05835986
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05846789-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0584678
 9)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Toci +/- S
 OC Chemo for Metastatic Triple Negative and ER-positive\, HER2-negative Br
 east Cancers\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05846789
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05233397-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0523339
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: ACTEMRA® 
 for the Treatment of Pediatric Adamantinomatous Craniopharyngioma\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05233397
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06037460-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0603746
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: TocilizuMa
 b discontinuAtion in GIant Cell Arteritis\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tociliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06037460
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06297096-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0629709
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: Study of t
 he Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis 
 and Interstitial Lung Disease\nEstimated primary completion: 30 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06297096
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589634-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0758963
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: A Study Ev
 aluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release S
 yndrome With Ramantamig Administration in Participants With Relapsed/Refra
 ctory Multiple Myeloma\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07589634
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0713889
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Immunosupp
 ressant Management in Rheumatology Patients Undergoing Elective Total Shou
 lder Arthroplasty\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043674-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0604367
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Phase 2 St
 udy of Glofitamab Monotherapy & With Polatuzumab Vedotin\, Pirtobrutinib\,
  or Atezolizumab in Richter's Transformation\nEstimated primary completion
 : 15 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 cilizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06043674
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04408638-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0440863
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: A Phase II
 I Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplati
 n vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participan
 ts With Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated prima
 ry completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04408638
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04561986-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0456198
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: TocIlizuma
 b in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant 
 Recipients\nEstimated primary completion: June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04561986
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0273570
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3\, COVID-19.\nStudy:
  Randomized\, Embedded\, Multifactorial Adaptive Platform Trial for Commun
 ity- Acquired Pneumonia\nEstimated primary completion: June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT02735707
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052058-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0705205
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Triple-Bli
 nd Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of a
 n IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resis
 tant Major Depression in the Brazilian Public Health System (SUS)\nEstimat
 ed primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07052058
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07929051-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0792905
 1)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: A Study to
  Test Obrixtamig Treatment in People With Different Types of Advanced Canc
 er Who Took Part in a Previous Study With Obrixtamig\nEstimated primary co
 mpletion: 3 July 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07929051
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392814-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0739281
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: Study With
  Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy i
 n Patients With Acute Myeloid Leukemia\nEstimated primary completion: 10 J
 uly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 92814
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863480-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0686348
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: Tocilizuma
 b-aazg for Hemorrhage: Reduction of Ischemic Vascular Events\nEstimated pr
 imary completion: 30 July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06863480
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT05583
 617)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Safety and Efficacy of Multiple Treatments in Participants 
 With Multiple Myeloma\nEstimated primary completion: 31 July 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06381661-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0638166
 1)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Adaptive P
 latform Trial for Personnalisation of Sepsis Treatment in Children and Adu
 lts: a Multi-national\, Treatable Traits-guided\, Adaptive\, Exploratory\,
  Bayesian Basket Trial\nEstimated primary completion: 9 August 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06381661
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05869955-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280829
DTEND;VALUE=DATE:20280830
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0586995
 5)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1\, Rheumatoid Arthri
 tis.\nStudy: A Study of CC-97540\, CD-19-Targeted Nex-T CAR T Cells\, in P
 articipants With Severe\, Refractory Autoimmune Diseases (Breakfree-1)\nEs
 timated primary completion: 29 August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05869955
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113743-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT07113
 743)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: Part B- 
 G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Link
 ed Chronic Granulomatous Disease\nEstimated primary completion: 1 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07113
 743
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381936-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0438193
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3\, COVID-19.\nStudy:
  Randomised Evaluation of COVID-19 Therapy\nEstimated primary completion: 
 30 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 cilizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04381936
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801638-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Actemra / RoActemra (tocilizumab): Phase na readout est. (NCT078016
 38)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase na.\nStudy: Anticoagu
 lation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in 
 Acute Cerebral Venous Thrombosis\nEstimated primary completion: 30 Septemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0780
 1638
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04871191-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0487119
 1)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: Study of S
 alvage Therapy to Treat Patients With Granulomatosis With Polyangiitis\nEs
 timated primary completion: October 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04871191
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595900-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT07595
 900)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: Tocilizu
 mab for the Treatment of Refractory Granulomatous Lobular Mastitis\nEstima
 ted primary completion: 30 October 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07595900
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335562-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20281114
DTEND;VALUE=DATE:20281115
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0733556
 2)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: A Study to
  Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel 
 / Zola-cel)\, CD19-CAR T Cells\, Versus Standard of Care in Participants W
 ith Active Systemic Sclerosis\nEstimated primary completion: 14 November 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07335562
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934044-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0693404
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Study Ev
 aluating the Pharmacokinetics\, Safety\, and Efficacy of Cevostamab in Chi
 nese Participants With Relapsed or Refractory Multiple Myeloma\nEstimated 
 primary completion: 15 November 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06934044
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910568-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0491056
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Study Ev
 aluating the Safety\, Pharmacokinetics\, and Activity of Cevostamab in Par
 ticipants With Relapsed or Refractory Multiple Myeloma\nEstimated primary 
 completion: 21 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04910568
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06033196-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0603319
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Tocilizuma
 b in Lung Transplantation\nEstimated primary completion: 8 January 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06033196
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870681-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2/3 readout est. (NCT07870
 681)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2/3.\nStudy: Infarct 
 Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke 
 Undergoing Endovascular Thrombectomy - ILLUMINATE\nEstimated primary compl
 etion: 31 January 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07870681
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115745-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0711574
 5)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Study of
  Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With S
 evere\, Refractory Autoimmune Diseases\nEstimated primary completion: 15 M
 arch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 115745
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03075696-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT03075
 696)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Dose E
 scalation Study of Glofitamab (RO7082859) as a Single Agent and in Combina
 tion With Obinutuzumab\, Administered After a Fixed\, Single Pre-treatment
  Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-
 hodgkin's Lymphoma\nEstimated primary completion: 30 March 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03075696
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825064-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290413
DTEND;VALUE=DATE:20290414
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0782506
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Cevostamab
  in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting 
 CAR T-Cell Therapy in Participants With Previously Treated Multiple Myelom
 a\nEstimated primary completion: 13 April 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07825064
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05169515-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0516951
 5)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Study Ev
 aluating the Safety\, Pharmacokinetics\, and Efficacy of Mosunetuzumab or 
 Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With
  B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 30 April 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05169515
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06654882-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0665488
 2)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: Trial of S
 equential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis\
 nEstimated primary completion: 30 May 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06654882
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889232-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT07889
 232)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: Tocilizu
 mab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small C
 ell Lung Cancer\nEstimated primary completion: 31 May 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07889232
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643038-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 4 readout est. (NCT0764303
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 4\, Rheumatoid Arthri
 tis.\nStudy: Treatment Strategy for Patients With RA-ILD\nEstimated primar
 y completion: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07643038
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637578-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0763757
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: A Study of
  Elranatamab Outpatient Administration in Patients With Relapsed/Refractor
 y Multiple Myeloma\nEstimated primary completion: October 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07637578
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07838974-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0783897
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: Adding Ana
 kinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Mel
 anoma Patients 50 Years of Age or Older\nEstimated primary completion: 1 N
 ovember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tociliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07838974
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533775-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT05533
 775)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in 
 Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-C
 ell Non-Hodgkin Lymphoma\nEstimated primary completion: 30 November 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05533775
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708038-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0770803
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: Anti-Inter
 leukin-6 (IL6) in Calciphylaxis\nEstimated primary completion: March 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07708038
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629583-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20300329
DTEND;VALUE=DATE:20300330
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0762958
 3)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: To Evaluat
 e the Effects of Cevostamab in Participants With Systemic Lupus Erythemato
 sus With or Without Active Lupus Nephritis\nEstimated primary completion: 
 29 March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tocili
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07629583
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281027-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0728102
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: COMparison
  Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"\nEstimated pri
 mary completion: 31 March 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07281027
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573332-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0757333
 2)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Safety a
 nd Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibo
 dy Positive Neuromyelitis Optica Patients\nEstimated primary completion: 1
  August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tociliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07573332
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04246086-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20300906
DTEND;VALUE=DATE:20300907
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT04246
 086)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Safety\, Pharmacokinetics\, and Efficacy of Mosunetuzumab +
  Lenalidomide (+Len)\, and the Safety\, Tolerability\, and Pharmacokinetic
 s of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymp
 homa\nEstimated primary completion: 6 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04246086
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT03424
 005)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Efficacy and Safety of Multiple Treatment Combinations in P
 atients With Metastatic or Locally Advanced Breast Cancer\nEstimated prima
 ry completion: 30 September 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493317-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20310206
DTEND;VALUE=DATE:20310207
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0749331
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Neutralizi
 ng Interleukin (IL)-6\nEstimated primary completion: 6 February 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07493317
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05091424-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20310210
DTEND;VALUE=DATE:20310211
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0509142
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Study Ev
 aluating the Safety\, Efficacy\, and Pharmacokinetics of Mosunetuzumab and
  a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With R
 elapsed or Refractory Chronic Lymphocytic Leukemia\nEstimated primary comp
 letion: 10 February 2031. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05091424
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870278-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20310705
DTEND;VALUE=DATE:20310706
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0787027
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: A Clinical
  Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)\nE
 stimated primary completion: 5 July 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07870278
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05833763-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0583376
 3)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: A Phase 2 
 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients Wit
 h Prior BTK Inhibitor Exposure.\nEstimated primary completion: April 2032.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05833763
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570173-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20331018
DTEND;VALUE=DATE:20331019
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2/3 readout est. (NCT07570
 173)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2/3.\nStudy: A Clinic
 al Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK
 -1045-005)\nEstimated primary completion: 18 October 2033. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07570173
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709000-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20331116
DTEND;VALUE=DATE:20331117
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0770900
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: A Clinical
  Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)\nEstimated pr
 imary completion: 16 November 2033. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07709000
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594067-6083@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20421130
DTEND;VALUE=DATE:20421201
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1 readout est. (NCT0759406
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1.\nStudy: TCR1188-AB
 C Cells in KRAS-mutated Cancers\nEstimated primary completion: November 20
 42. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07594067
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
